Pretreatment maternal lifestyle and outcomes of assisted reproduction: an Italian cohort study

ObjectiveWe investigated whether lifestyle affects assisted reproduction technology (ART) outcomes.DesignCohort study.SettingItalian fertility unit.ParticipantsFrom September 2014 to December 2016, women from couples presenting for evaluation and eligible for ART were invited to participate. Information on alcohol intake, current smoking and leisure physical activity (PA) during the year before the interview was collected, using a structured questionnaire. We considered the ART outcomes of the cycle immediately following the interview.Primary and secondary outcome measuresThe primary outcome measure was cumulative pregnancy rate per retrieval. Secondary measures were number of retrieved oocytes, embryo transfer and live birth.ResultsIn 492 women undergoing an ART cycle, 427 (86.8%) underwent embryo transfer, 157 (31.9%) had at least one clinical pregnancy and 121 (24.6%) had live birth. The cumulative pregnancy rate per retrieval was 33.3% (95% CI 28.5% to 38.7%). In women in the third tertile of alcohol intake, adjusted relative risk was 0.97 (95% CI 0.87 to 1.08), 0.90 (95% CI 0.62 to 1.30) and 0.89 (95% CI 0.57 to 1.37) for embryo transfer, clinical pregnancy and live birth, respectively. The corresponding figures in women currently smoking more than 5 cigarettes/day were 1.00 (95% CI 0.88 to 1.16), 0.94 (95% CI 0.60 to 1.48) and 1.14 (95% CI 0.68 to 1.90), and in women with PA ≥5 hours/week were 0.93 (95% CI 0.79 to 1.08), 0.44 (95% CI 0.22 to 0.90) and 0.48 (95% CI 0.22 to 1.05), respectively.ConclusionThere were no significant differences in in vitro fertilisation outcomes among women who used alcohol or tobacco in the year prior to treatment. Conservatively, all women should be advised to limit substance abuse. Moreover, our study suggested that maintaining a moderate, but not high, level of PA could be beneficial.

Download Full-text

Uterus Size May Affect Reproductive Outcome in Women with Adenomyosis After Gnrh- Agonist Pretreatment Undergoing Frozen Embryo Transfer Cycles: A Retrospective Cohort Study

10.21203/rs.3.rs-122461/v1 ◽

2020 ◽

Author(s):

Wei Xiong ◽

Ruiyi Tang ◽

Peng Wu ◽

Zhengyi Sun ◽

jingran zhen ◽

...

Keyword(s):

Cohort Study ◽

Pregnancy Rate ◽

Embryo Transfer ◽

Live Birth ◽

Gnrh Agonist ◽

Retrospective Cohort Study ◽

Pregnancy Outcomes ◽

Retrospective Cohort ◽

Clinical Pregnancy ◽

Frozen Embryo Transfer

Abstract Background: GnRH-agonist is used to treat adenomyosis, but its efficacy in adenomyosis patients with uterine enlargement undergoing frozen embryo transfer (FET) is unclear. Methods：The retrospective cohort study comprised 112 adenomyosis patients with uterine enlargement undergoing the first FET circle. A long-term GnRH-a pretreatment was administered to 112 patients with uterine enlargement. These patients were divided into two groups according to the therapeutic effect: patients with a normal-size uterus after GnRH-a treatment (GN group) and patients with an enlarged uterus after GnRH-a treatment (GL group). Results：Not all patients can shrink their uterus to a satisfactory level. After receiving GnRH-a pretreatment, the uterus returned to normal size in 77% of patients (GN group), and 23% of patients had a persistently enlarged uterus (GL group). The pregnancy rate, clinical pregnancy rate, ongoing pregnancy rate, and live birth rate were significantly higher in the GN group than in the GL group. Controlling for the confounding factors, normal uterus size (odds ratio [OR] 4.50; P=0.03) and low body mass index (OR 3.13; P=0.03) affected the odds of achieving live birth. The cut-off value selected on the ROC curve of uterus volume after GnRH-a treatment for detecting live birth was 144.7Conclusions：GnRH-a pretreatment was associated with the regression of adenomyosis lesions and improved clinical pregnancy outcomes in the adenomyosis patients with uterine enlargement whose lesion are GnRH-a susceptible on FET cycles. However, about a quarter of patients may not be less responsive to GnRH-a and have poorer pregnancy outcomes, especially in overweight women.

Download Full-text

Outcome of mock embryo transfer before the first IVF cycle: A randomized control trial

International Journal of Reproductive BioMedicine ◽

10.18502/ijrm.v13i11.7962 ◽

2020 ◽

Author(s):

Amol Borkar ◽

Amit Shah ◽

Anil Gudi ◽

Roy Homburg

Keyword(s):

Pregnancy Rate ◽

Embryo Transfer ◽

Live Birth ◽

Birth Rate ◽

Multiple Pregnancy ◽

Live Birth Rate ◽

Clinical Pregnancy ◽

Clinical Pregnancy Rate ◽

Secondary Outcome ◽

Significant Difference

Background: There is a lack of agreement among fertility specialists with regard to the routine use of mock embryo transfer (MET) before each in vitro fertilization (IVF) treatment cycle. While MET may be beneficial with previous difficult embryo transfer cases, its routine use before first IVF cycle has not been evaluated. Objective: To find out the effect of MET before the first IVF cycle on clinical pregnancy rate. Materials and Methods: This is a single-centre randomized controlled trial with a balanced randomization (1:1), carried out between November 2015 and October 2017, with 200 subjects at Homerton university hospital, London, randomized into either MET or control. The primary outcome was clinical pregnancy rate (detection of heart activity on the ultrasound scan), the secondary outcome measures were live birth rate, miscarriage and multiple pregnancy rates, difficult ETs, rate of blood or mucus on the catheter tip. Results: No significant differences were observed in the baseline or cycle characteristics between the two groups. The clinical pregnancy rate was similar between the MET and control groups based on both intension to treat and per protocol analyses (p = 0.98, p = 0.92, respectively). Additionally, no significant difference was seen in the live birth rate in both groups on intension to treat and per protocol analyses (p = 0.67, p = 0.47), respectively. Conclusion: Our study concludes that MET prior to first IVF cycle may not improve the success rate in young women without risk factors for a difficult embryo transfer. Key words: IVF, Mock embryo transfer, Pregnancy outcomes, Live birth.

Download Full-text

Live Birth Rate of Fresh Embryo Transfer with GnRH Agonist Long Protocol is Higher Than Frozen Embryo Transfer

10.21203/rs.3.rs-70853/v1 ◽

2020 ◽

Author(s):

Xiaoyan Ding ◽

Jingwei Yang ◽

Lan Li ◽

Na Yang ◽

Ling Lan ◽

...

Keyword(s):

Pregnancy Rate ◽

Embryo Transfer ◽

Live Birth ◽

Pregnancy Loss ◽

Birth Rate ◽

Implantation Rate ◽

Live Birth Rate ◽

Clinical Pregnancy ◽

Fresh Embryo Transfer ◽

Long Protocol

Abstract Background: Along with progress in embryo cryopreservation, especially in vitrification has made freeze all strategy more acceptable. Some studies found comparable or higher live birth rate with frozen embryo transfer (FET) than with fresh embryo transfer（ET）in gonadotropin releasing hormone antagonist (GnRH-ant) protocol. But there were no reports about live birth rate differences between fresh ET and FET with gonadotropin releasing hormone agonist (GnRH-a) long protocol. The aim of this study is to analyze whether patients benefit from freeze all strategy in GnRH-a protocol from real-world data.Methods: This is a retrospective cohort study, in which women undergoing fresh ET or FET with GnRH-a long protocol at Chongqing Reproductive and Genetics Institute from January 2016 to December 2018 were evaluated. The primary outcome was live birth rate. The secondary outcomes were implantation rate, clinical pregnancy rate, pregnancy loss and ectopic pregnancy rate.Results: A total of 7,814 patients met inclusion criteria, implementing 5,216 fresh ET cycles and 2,598 FET cycles, respectively. The demographic characteristics of the patients were significantly different between two groups, except BMI. After controlling for a broad range of potential confounders (including age, infertility duration, BMI, AMH, no. of oocytes retrieved and no. of available embryos), multivariate logistic regression analysis demonstrated that there was no significant difference in terms of clinical pregnancy rate, ectopic pregnancy rate and pregnancy loss rate between two groups (all P>0.05). However, the implantation rate and live birth rate of fresh ET group were significantly higher than FET group (P<0.001 and P=0.012, respectively).Conclusion: Compared to FET, fresh ET following GnRH-a long protocol could lead to higher implantation rate and live birth rate in infertile patients underwent in vitro fertilization (IVF). The freeze all strategy should be individualized and made with caution especially with GnRH-a long protocol.

Download Full-text

P–159 Slow-growing embryos should be frozen on day 5

Human Reproduction ◽

10.1093/humrep/deab130.158 ◽

2021 ◽

Vol 36 (Supplement_1) ◽

Author(s):

M J Zamora ◽

I Katsouni ◽

D Garcia ◽

R Vassena ◽

A Rodríguez

Keyword(s):

Pregnancy Rate ◽

Embryo Transfer ◽

Live Birth ◽

Birth Rate ◽

Live Birth Rate ◽

Study Groups ◽

Pregnancy Rates ◽

Clinical Pregnancy ◽

Patient Counselling ◽

Slow Growing

Abstract Study question What is the live birth rate after frozen embryo transfer (FET) of slow-growing embryos frozen on day 5 (D5) or on day 6 (D6)? Summary answer The live birth rate after single FET is significantly higher for slow-growing embryos frozen on D5 compared to those frozen on D6. What is known already Most data on the outcomes of blastocyst transfer stem from studies that evaluate fresh transfer from normal growing D5 blastocyst ET. However not all embryos will begin blastulation nor reach the fully expanded stage by D5; those are the slow-growing embryos. Studies that compare D5 to D6 embryos in FET cycles show contradictory results. Some have reported higher clinical pregnancy rates after D5 FET, while others have reported similar outcomes for D5 and D6 cryopreserved blastocyst transfers. There is a lack of evidence regarding the best approach for vitrifying embryos that exhibit a slow developmental kinetic. Study design, size, duration This retrospective cohort study included 821 single FET of slow-growing embryos frozen on D5 or D6, belonging to patients undergoing in vitro fertilization with donor oocytes between January 2011 and October 2019, in a single fertility center. The origin of blastocysts was either supernumerary embryos after fresh embryo transfer or blastocysts from freeze-all cycles. All embryos were transferred 2- 4h after thawing. Participants/materials, setting, methods We compared reproductive outcomes of slow-growing embryos frozen on D5 versus (n = 442) slow-growing embryos frozen on D6 (n = 379). D5 group consisted in embryos graded 0, 1, 2 of Gardner scale and frozen on D5. Similarly, D6 group consisted in embryos graded 3, 4, 5 of Gardner scale (blastocyst stage) and frozen on D6. Differences in pregnancy rates between study groups were compared using a Chi2 test. A p-value <0.05 was considered statistically significant. Main results and the role of chance Baseline characteristics were comparable between study groups. Overall, mean age of the woman was 42.3±5.4 years old; donor sperm was used in 25% of cycles, and it was frozen in 73.2% of cycles. Pregnancy rates were significantly higher when transferring slow D5 embryos compared to D6 for all the pregnancy outcomes analyzed: biochemical pregnancy rate was 27.7% vs 20.2%, p < 0.016; clinical pregnancy rate was 17.5% vs 10.2%, p < 0.004); ongoing pregnancy rate was: 15.7% vs 7.8% (p < 0.001); live birth rate was: 15.4% vs 7.5%, (p < 0.001). These results suggest that when embryos exhibit a slow development behavior (not reaching full blastocysts at D5), waiting until D6 for blastulation and expansion does not improve clinical outcomes. Vitrification at D5 will should the preferred option in cases where the oocyte is assumed of high quality Limitations, reasons for caution The retrospective design of the study is its main limitation. Also, morphology as sole selection criterion for transfer. However, blastocyst morphology is a very good predictor of implantation and pregnancy, and a good indicator of the embryo’s chromosomal status (higher euploidy rate in higher morphological quality blastocysts). Wider implications of the findings: These results can help to the standardization of laboratory protocols. As the decision of vitrifying slow developing embryos on D5 or D6 is made by the laboratory team or by the gynaecologist in agreement with the patient, having an evidence based strategy simplifies patient counselling and decision making. Trial registration number Not applicable

Download Full-text

O-232 Higher clinical pregnancy rate after oxytocin-receptor antagonist administration around the time of embryo transfer: A systematic review and meta-analysis of eleven RCTs

Human Reproduction ◽

10.1093/humrep/deab128.056 ◽

2021 ◽

Vol 36 (Supplement_1) ◽

Author(s):

K Neumann ◽

G Griesinger

Keyword(s):

Relative Risk ◽

Receptor Antagonist ◽

Pregnancy Rate ◽

Embryo Transfer ◽

Live Birth ◽

Meta Analysis ◽

Oxytocin Receptor ◽

Clinical Pregnancy ◽

Clinical Pregnancy Rate ◽

Receptor Antagonists

Abstract Study question Does the administration of an oxytocin-receptor antagonist around time of embryo transfer in IVF impact the likelihood to achieve a clinical pregnancy? Summary answer Administration of oxytocin-receptor antagonists around embryo transfer increases the likelihood of clinical pregnancy achievement. What is known already Uterine contractions occurring around time of embryo transfer have been described as one possible mechanism of failure of implantation of an embryo in the context of in-vitro fertilization (IVF). Hence the utilization of oxytocin-receptor antagonists was evaluated in randomized clinical trials (RCT) as a therapeutic approach. The compound Atosiban was studied by most RCTs (summarized in Huang et al. 2017). Recently further studies have become available which also investigated the novel agents Barusiban and Nolasiban. This systematic review collates the evidence of all drugs functioning as oxytocin-receptor antagonists which have been investigated in RCTs on IVF treatment so far. Study design, size, duration Multiple literature databases were searched for randomized controlled studies comparing the outcome of IVF cycles with administration of an oxytocin-receptor antagonist in the time period before, during or after embryo transfer versus placebo or nil in IVF patients. Meta-analyses were performed using standard procedures in the software program RevMan v.5.4. All analyses were done per randomized patient, wherever feasible. Participants/materials, setting, methods Eleven RCTs were identified and included in the meta-analysis. Seven utilized the agent Atosiban, one Barusiban and three Nolasiban. These drugs were administered either intravenously, subcutaneously or orally. The patient populations were heterogenous (fresh cycle, frozen-thawed cycle, endometriosis, implantation failure or general IVF-population) between trials. Only four studies reported live birth rates whereas all RCTs reported clinical pregnancy rate. Main results and the role of chance Administration of an oxytocin-receptor antagonist around embryo transfer increases the likelihood of live birth (relative risk: 1.1, 95% CI: 0.99-1.22, p = 0.06, I2=31%, four RCTs, n = 2,510). Accordingly, the ongoing pregnancy rate is increased (relative risk: 1.14, 95% CI: 1.03-1.26, p = 0.01, I2=18%, four RCTs, n = 2,510) as well as the clinical pregnancy rate (relative risk: 1.31, 95% CI: 1.13-1.51, p = 0.0002, I2=61%, eleven RCTs, n = 3,611) by administration of an oxytocin-receptor antagonist. The risk to suffer a miscarriage, however, is not influenced by an oxytocin-receptor antagonist administration (relative risk: 0.90, 95% CI: 0.72-1.12, p = 0.35, I2=0%, seven RCTs, n = 2,936). The risk of multiple pregnancy is not different between groups (relative risk: 1.05 95% CI: 0.81-1.36, p = 0.73, I2=5%, seven RCTs, n = 3,014) as is the risk for an ectopic pregnancy (relative risk: 0.88 95% CI: 0.43-1.8, p = 0.73, I2=0%, four RCTs, n = 2,714). Limitations, reasons for caution Methodological rigor is heterogenous between trials and some of the evidence is of poor quality. Evaluation of included studies is still ongoing and queries are pending. Additionally, there is heterogeneity between patient populations and definition of outcomes; only four RCTs report ongoing pregnancies and live births. Wider implications of the findings The administration of oxytocin-receptor antagonists around embryo transfer increases the pregnancy rate and may be a promising approach to enhance the likelihood to achieve a live birth per embryo transfer. Trial registration number n.a.

Download Full-text

Optimal Duration of Progesterone Treatment before Cryopreserved-Thawed Embryo Transfer

Gynecology & Reproductive Health ◽

10.33425/2639-9342.1145 ◽

2021 ◽

Vol 5 (2) ◽

Author(s):

Suat Suphan Ersahin ◽

Aynur Ersahin

Keyword(s):

Treatment Group ◽

Pregnancy Rate ◽

Embryo Transfer ◽

Live Birth ◽

Clinical Pregnancy ◽

Progesterone Treatment ◽

Optimal Duration ◽

The Difference ◽

Group 2 ◽

Thawed Embryo Transfer

Objective: To investigate the optimal duration of progesterone therapy before cryopreserved-thawed embryo transfer and its impact on clinical pregnancy and live birth rates. Methods: Five hundreds women undergoing cryopreserved-thawed embryo transfer were included in the study. These patients had a total of 500 embryos frozen on day 3 (n = 200), day 4 (n = 100), day 5 (n = 150) and day 6 (n = 50). Artificial endometrial preparation was successfully performed in all participants. If the endometrial thickness reached a minimum of 8 mm or in the presence of a triple-line view, the patients were divided into four different groups and each group into two subgroups according to the estimated duration of progesterone treatment to be used. Group 1 (n = 200): This group consisted of patients with day 3 embryo transfer. While 100 of 200 patients received embryo transfer after 3 days of progesterone treatment, the remaining 100 patients received embryo transfer after 4 days of progesterone treatment. Group 2 (n = 100): This group consisted of patients who underwent day 4 embryo transfer. While 50 of 100 patients had embryo transfer after 4 days of progesterone treatment, the remaining 50 patients received embryo transfer after 5 days of progesterone treatment. Group 3 (n = 150): This group consisted of patients who received day 5 embryo transfer. While 75 of 150 patients received embryo transfer after 5 days of progesterone treatment, the remaining 75 patients received embryo transfer after 6 days of progesterone treatment. Group 4 (n = 50): While 25 of 50 patients received embryo transfer after 6 days of progesterone treatment, the remaining 25 patients received embryo transfer after 7 days of progesterone treatment. The primary outcome measure of our study was to evaluate clinical pregnancy rate (CPR), ongoing pregnancy rate (OPR), live birth rate (LBR) and miscarriage rate per pregnancy. Results: Clinical pregnancy rates were found in 50 of 100 (50%) cases who were given progesterone for 3 days. Of the 100 cases who were given progesterone for 4 days, 40 clinical pregnancy was detected (40%). Both OPR and LBR were found to be significantly lower in patients who received 4 days of progesterone treatment compared to those given 3 days. The rates of miscarraige (9.09%) in patients who received progesterone treatment for 4 days were significantly higher than those who received progesterone for 3 days (5.8%). In Group 2 both OPR and LBR were found to be significantly lower in patients who received 5 days of progesterone treatment compared to those given 4 days. The rate of miscarraige (25.0%) was significantly higher in patients who received progesterone treatment for 5 days compared to those who received progesterone for 4 days (33.3%). When 75 patients in group III who underwent embryo transfer on the fifth day and received progesterone treatment for 5 days and 75 patients who were given progesterone treatment for 6 days were evaluated in terms of CPR, OPR and LBR the difference was statistically significant between the two gruops. When patients in group IV were evaluated in terms of CPR, OPR and LBR the difference was statistically insignificant. Conclusions: Extending the progestereone usage period one day before embryo transfer has been found beneficial in patients who have been transferred for only fifth day.

Download Full-text

P–318 Short (seven days) versus conventional (fourteen days) estrogen priming in an artificial frozen embryo transfer cycle: a randomised controlled trial

Human Reproduction ◽

10.1093/humrep/deab130.317 ◽

2021 ◽

Vol 36 (Supplement_1) ◽

Author(s):

A Racca ◽

S Santos-Ribeiro ◽

D Panagiotis ◽

L Boudry ◽

S Mackens ◽

...

Keyword(s):

Pregnancy Rate ◽

Embryo Transfer ◽

Live Birth ◽

Transvaginal Ultrasound ◽

Clinical Pregnancy ◽

Frozen Embryo Transfer ◽

Significant Difference ◽

Group A ◽

Group B ◽

The Impact

Abstract Study question What is the impact of seven days versus fourteen days’ estrogen (E2) priming on the clinical outcome of frozen-embryo-transfer in artificially prepared endometrium (FET-HRT) cycles? Summary answer No significant difference in clinical/ongoing pregnancy rate was observed when comparing 7 versus 14 days of estrogen priming before starting progesterone (P) supplementation. What is known already One (effective) method for endometrial preparation prior to frozen embryo transfer is hormone replacement therapy (HRT), a sequential regimen with E2 and P, which aims to mimic the endocrine exposure of the endometrium in a physiological cycle. The average duration of E2 supplementation is generally 12–14 days, however, this protocol has been arbitrarily chosen whereas, the optimal duration of E2 implementation remains unknown. Study design, size, duration This is a single-center, randomized, controlled, open-label pilot study. All FET-HRT cycles were performed in a tertiary centre between October 2018 and December 2020. Overall, 150 patients were randomized of whom 132 were included in the analysis after screening failure and drop-out. Participants/materials, setting, methods The included patients were randomized into one of 2 groups; group A (7 days of E2 prior to P supplementation) and group B (14 days of E2 prior to P supplementation). Both groups received blastocyst stage embryos for transfer on the 6th day of vaginal P administration. Pregnancy was assessed by an hCG blood test 12 days after FET and clinical pregnancy was confirmed by transvaginal ultrasound at 7 weeks of gestation. Main results and the role of chance Following the exclusion of drop-outs and screening failures, 132 patients were finally included both in group A (69 patients) or group B (63 patients). Demographic characteristics for both groups were comparable. The positive pregnancy rate was 46.4% and 53.9%, (p 0.462) for group A and group B, respectively. With regard to the clinical pregnancy rate at 7 weeks, no statistically significant difference was observed (36.2% vs 36.5% for group A and group B, respectively, p = 0.499). The secondary outcomes of the study (biochemical pregnancy, miscarriage and live birth rate) were also comparable between the two arms for both PP and ITT analysis. Multivariable logistic regression showed that the HRT scheme is not associated with pregnancy rate, however, the P value on the day of ET is significantly associated with the pregnancy outcome. Limitations, reasons for caution This study was designed as a proof of principle trial with a limited study population and therefore underpowered to determine the superiority of one intervention over another. Instead, the purpose of the present study was to explore trends in outcome differences and to allow us to safely design larger RCTs. Wider implications of the findings: The results of this study give the confidence to perform larger-scale RCTs to confirm whether a FET-HRT can be performed safely in a shorter time frame, thus, reducing the TTP, while maintaining comparable pregnancy and live birth rates. Trial registration number NCT03930706

Download Full-text

Does Estradiol Orally and Vaginally Administered Together Impact Live Birth and Neonatal Outcome in Artificial Frozen-thawed Embryo Transfer Cycles: A Retrospective Cohort Study

10.21203/rs.3.rs-42796/v1 ◽

2020 ◽

Author(s):

Yuan Liu ◽

Yixia Yang ◽

Xinting Zhou ◽

Yanmei Hu ◽

Yu Wu

Keyword(s):

Pregnancy Rate ◽

Preterm Delivery ◽

Embryo Transfer ◽

Live Birth ◽

Clinical Pregnancy ◽

Clinical Pregnancy Rate ◽

Delivery Rate ◽

Serum Estradiol ◽

Frozen Thawed Embryo Transfer ◽

Thawed Embryo Transfer

Abstract Background: Previous studies have demonstrated that newborns from fresh embryo transfer are with higher risk of small for gestation (SGA) rate than those from frozen-thawed embryo transfer (FET). It is suggested that supraphysiologic serum estradiol in controlled ovarian stimulation (COS)is one of reasons. Out study aims to investigate whether exogenous estradiol delivered regimens have an impact on live birth rate and singleton birthweight in hormone replacement (HRT)-FET cycles.Methods:This retrospective study involved patients undergoing their first FET with HRT endometrium preparation followed by two cleavage-staged embryos transfer, comparing orally and vaginal estradiol tablets (OVE) group versus oral estradiol tablets (OE) group from January 2015 to December 2018 at our center. A total of 792 patients fulfilled the criteria, including 282 live birth singletons. Live birth was the primary outcome. Secondary outcome included clinical pregnancy rate, singleton birthweight, large for gestational age (LGA) rate, SGA rate, preterm delivery rate. Results:Patients in OVE group achieved higher serum estradiol level with more days of estradiol treatment. No difference in live birth (Adjusted OR 1.327; 95%CI 0.982, 1.794, p=0.066) and clinical pregnancy rate (Adjusted OR 1.278; 95%CI 0.937, 1.743, p=0.121) was found between OVE and OE groups. Estradiol route did not affect birth weight (β=-30.962, SE=68.723, p=0.653), the odds of LGA (Adjusted OR 1.165; 95%CI 0.545, 2.490, p=0.694), the odds of SGA (Adjusted OR 0.569; 95%CI 0.096, 3.369, p=0.535) or the preterm delivery rate (Adjusted OR 0.969; 95%CI 0.292, 3.214, p=0.959).Conclusion:Estrogen orally and vaginally together did not have an impact on clinical outcomes and singleton birthweight compared to estrogen orally taken, but was accompanied with relative higher serum E2 level and potential maternal undesirable risks.

Download Full-text

Twice vitrification-warming procedures has no effect on frozen-thawed embryo transfer outcomes

10.21203/rs.3.rs-1059310/v1 ◽

2021 ◽

Author(s):

xiaoyue Shen ◽

Min Ding ◽

Yuan Yan ◽

Shanshan Wang ◽

jianjun Zhou ◽

...

Keyword(s):

Pregnancy Rate ◽

Embryo Transfer ◽

Live Birth ◽

Birth Rate ◽

Live Birth Rate ◽

Clinical Pregnancy ◽

Clinical Pregnancy Rate ◽

Miscarriage Rate ◽

Frozen Thawed Embryo Transfer ◽

Thawed Embryo Transfer

Abstract Background To evaluate the frozen-thawed embryo transfer (FET) outcomes of repeated cryopreservation by vitrification of blastocysts derived from vitrified-warmed day3 embryos in patients who experienced implantation failure previously. Methods We retrospect the files of patients who underwent single frozen-thawed blastocyst transfer cycles in our reproductive medical center from January 2013 to December 2019. 127 patients transfer of vitrified-warmed blastocysts derived from vitrified-warmed day3 embryos were defined as twice-cryopreserved group. 1567 patients who transfer blastocysts that had experienced once vitrified-warmed were used as once-cryopreserved group. None of them was pregnant at the previous FET. The outcomes were compared between two groups after a 1:1 propensity score matching (PSM). Results The clinical pregnancy rate was 52.76%, live birth rate was 43.31% in twice-cryopreserved group. After PSM,108 pairs of patients were generated for comparison. The clinical pregnancy rate, live birth rate or miscarriage rate was not significantly different between two groups. Logistic regression analysis indicated that double vitrification-warming procedures did not affect FET outcomes in terms of clinical pregnancy rate (OR 0.83, 95%CI 0.47-1.42), live birth rate (OR 0.93, 95%CI 0.54-1.59), miscarriage rate (OR 0.72 95%CI 0.28-1.85). Furthermore, the pregnancy complications rate, gestational age or neonatal abnormalities rate between two groups was also comparable, while twice vitrification-warming procedures might increase the macrosomia rate (19.6% vs. 6.3%, P = 0.05). Conclusion Transfer of double vitrified-warmed embryo at cleavage stage and subsequent blastocyst stage did not affect live birth rate and neonatal abnormalities rate, but there was a tendency to increase macrosomia rate, which needs further investigation.

Download Full-text

Does estradiol orally and vaginally administered together impact live birth and neonatal outcomes in artificial frozen-thawed embryo transfer cycles: a retrospective cohort study

10.21203/rs.3.rs-42796/v2 ◽

2020 ◽

Author(s):

Yuan Liu ◽

Yixia Yang ◽

Jian Sun ◽

Xinting Zhou ◽

Yanmei Hu ◽

...

Keyword(s):

Pregnancy Rate ◽

Embryo Transfer ◽

Live Birth ◽

Birth Rate ◽

Live Birth Rate ◽

Clinical Pregnancy ◽

Neonatal Outcomes ◽

Serum Estradiol ◽

Frozen Thawed Embryo Transfer ◽

Thawed Embryo Transfer

Abstract Background: Previous studies have demonstrated that newborns from fresh embryo transfer have higher risk of small for gestation (SGA) rate than those from frozen-thawed embryo transfer (FET). It is suggested that supraphysiologic serum estradiol in controlled ovarian stimulation (COS) is one of reasons. Our study aims to investigate whether exogenous estradiol delivered regimens have an impact on live birth rate and neonatal outcomes in hormone replacement (HRT)-FET cycles. Methods: This was a retrospective study involving patients undergoing their first FET with HRT endometrium preparation followed by the transfer of two cleavage-staged embryos, comparing estradiol administered orally and vaginally (OVE group) versus estradiol administered orally (OE group) from January 2015 to December 2018 at our center. A total of 792 patients fulfilled the criteria, including 228 live birth singletons. The live birth rate was the primary outcome measure. Secondary outcome measures included clinical pregnancy rate, singleton birthweight, large for gestational age (LGA) rate, SGA rate, preterm delivery rate. Results: Patients in OVE group achieved higher serum estradiol level with more days of estradiol treatment. No difference in live birth (Adjusted OR 1.327; 95%CI 0.982, 1.794, p = 0.066) and clinical pregnancy rate (Adjusted OR 1.278; 95%CI 0.937, 1.743, p = 0.121) was found between OVE and OE groups. Estradiol route did not affect singletons birth weight (β = -30.962, SE = 68.723, p = 0.653), the odds of LGA (Adjusted OR 1.165; 95%CI 0.545, 2.490, p = 0.694), the odds of SGA (Adjusted OR 0.569; 95%CI 0.096, 3.369, p = 0.535) or the preterm delivery (Adjusted OR 0.969; 95%CI 0.292, 3.214, p = 0.959). Conclusion: Estrogen taken orally and vaginally together did not change live birth rate and singleton neonatal outcomes compared to estrogen taken orally, but was accompanied with relative higher serum E2 level and potential maternal undesirable risks.

Download Full-text